Danaher Releases 2020 Sustainability Report

- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today published its 2020 Sustainability Report, highlighting key environmental, social and governance developments at the Company and announcing new diversity and environmental goals.

Anchored in its Shared Purpose – Helping Realize Life's Potential – and empowered by the Danaher Business System, Danaher seeks to drive sustainability across three key pillars:

  • Innovation : Danaher's technologies advance research, improve health and protect the environment.
  • People : Danaher is committed to attracting, developing, engaging and retaining the best people to build and sustain the Company.
  • Environment : Danaher strives to reduce the environmental impact of its operations and products, and support customers in doing the same.

These pillars are supported by a foundation of integrity, compliance and sound governance, which the Company refers to as the Foundational Elements of its sustainability program.

Highlights from this year's report include:

  • Danaher's vital role in COVID-19 diagnostic testing and therapeutics and vaccine development . To date, Danaher's businesses have collectively enabled or produced more than 60 million COVID-19-related diagnostic tests and are involved in the majority of the more than 250 COVID-19 vaccine and therapeutic projects currently underway globally.
  • Danaher's newly-announced diversity goals . Danaher is committed to achieving the following goals by 2025 (compared to 2019 levels):
    1.  increasing the representation of women associates globally to 40% (from 35%); and
    2.  increasing People of Color representation among U.S. associates to 35% (from 31%).
  • Danaher's newly-announced environmental impact reduction goals : Danaher is committed to achieving the following goals by 2024 (compared to 2019 levels):
    1.  15% reduction in energy use (normalized to annual revenue);
    2.  15% reduction in Scope 1 and 2 greenhouse gas emissions (normalized to annual
    revenue); and
    3.  15% decrease in the percentage of non-hazardous/non-regulated waste sent to landfills
    or incinerators.

"We strive to be a purpose-led, high performance company which relies on the strength of the Danaher Business System and a commitment to integrity, compliance and sound governance to realize life's potential for all our stakeholders," says Rainer Blair , President & CEO. "Our innovative portfolio, the dedication of our passionate people, and our deeply ingrained commitment to continuous improvement amplify our opportunity to impact sustainability for the long term. As we rise-up to meet the world's challenges in this unique moment, we see a bright future ahead."

Danaher's sustainability report is available at https://sustainability.danaher.com/ . An infographic is available at https://sustainability.danaher.com/pdfs/2020SustainabilityHighlights.pdf .

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 67,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential . For more information, please visit www.danaher.com .

FORWARD LOOKING STATEMENTS

Statements in this release that are not strictly historical, including statements regarding the Company's sustainability initiatives, diversity and environmental impact reduction goals, COVID-19 related contributions and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher's SEC filings, including our 2019 Annual Report on Form 10-K and our first, second and third quarter 2020 Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/danaher-releases-2020-sustainability-report-301170308.html

SOURCE Danaher Corporation

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×